Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly misleading investors about its business prospects during the pandemic [1][2]. Group 1: Allegations - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [2]. - It is alleged that the company downplayed the severity of issues affecting its business and the necessary changes to address these issues [2]. - The complaint states that Petco overstated its ability to achieve sustainable and profitable growth, leading to a decline in stock price when the truth was revealed [2]. Group 2: Class Action Participation - Investors who purchased Petco securities between January 14, 2021, and June 5, 2025, may be eligible to participate in the class action [1][3]. - Shareholders interested in serving as lead plaintiffs can contact the firm, but participation is not required to be eligible for recovery [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is successful [4].

South Korea’s ambitious plan to improve corporate governance standards got a boost after the parliament voted to approve changes that will help protect the rights of minority shareholders https://t.co/OBq2Hb27ea ...

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Leading shareholder rights law firm Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation (NASDAQ: MASI). The investigation centers on whether Masimo’s leadership failed to uphold their responsibilities to shareholders and may have violated corporate governance obligations. Why Is Johnson Fistel Investigating Masimo Corporation?The investigation follows a cour ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Avis Budget Group, Inc. (NASDAQ:CAR) on behalf of long-term stockholders following a class action complaint that was filed against Avis on April 25, 2025 with a Class Period from February 16, 2024 and February 10, 2025. Our investigation concerns whether the board of directors of Avis have breached their fiduciary duties to the company. The l ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Napco Security Technologies, Inc. (NASDAQ: NSSC) on behalf of long-term stockholders following a class action complaint that was filed against NAPCO on April 25, 2025 with a Class Period from February 5, 2024, to February 3, 2025. Our investigation concerns whether the board of directors of NAPCO have breached their fiduciary duties to the co ...

HALIFAX, Nova Scotia, June 26, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce its shareholders voted in favour of all items of business brought before them at the Company's Annual and Special Meeting of Shareholders (“Meeting”) held on June 25, 2025 in Halifax, Nova Scotia. Details of the Meeting are provided below. Appointment of Board and Executive At the Meeting, shareholders voted in favour of Erdene management’s n ...

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...